Name one biotech that has done well after a reverse split. It's normally a disaster.
BPAX: dropped from $24 to $1.50 soon after R/S.
CYCC: dropped from $56 to $5 soon after R/S.
DSCO: dropped from $94 to $3 soon after R/S.
CTIC: dropped from $1,783 to $1.50 soon after R/S.
The overwhelming majority of biotechs got crushed after a R/S.
You might find one exception out of a hundred.
It really is the kiss of death.